Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology	⤷ Get Started Free	AC-16043	⤷ Get Started Free
Sigma-Aldrich	⤷ Get Started Free	O-002_CERILLIAN	⤷ Get Started Free
LGC Standards	⤷ Get Started Free	LGCAMP0672.10-01	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 5, 2025

Introduction

XTAMPZA ER (oxymorphone extended-release) is a prescription opioid analgesic marketed for managing moderate to severe pain. As a Schedule II controlled substance, its manufacturing and distribution are heavily regulated, with a focus on ensuring quality, security, and compliance. Central to its production is sourcing high-quality bulk Active Pharmaceutical Ingredient (API), oxymorphone hydrochloride, which necessitates sourcing from reputable suppliers worldwide.

This article provides an in-depth analysis of the primary API sources for XTAMPZA ER, examining the global landscape, regulatory considerations, key suppliers, and market trends. It aims to guide pharmaceutical professionals, manufacturers, and regulatory bodies in understanding the API supply chain critical to the production of this opioid medication.

Overview of API Requirements for XTAMPZA ER

The API used in XTAMPZA ER must meet stringent standards compliance to ensure efficacy, safety, and regulatory approval. Given its extended-release formulation, the API must possess high purity, stability, and consistent physicochemical properties. Additionally, API sourcing must align with Good Manufacturing Practices (GMP) as stipulated by regulatory agencies like the FDA, EMA, and others.

Key API Attributes for XTAMPZA ER:

Chemical Purity: ≥ 99.9%
Particle Size Distribution: Consistent for formulation stability
Impurity Profile: Minimal residual solvents and impurities
Supplier Certification: GMP compliance, cGMP certification preferred

Global Landscape of API Suppliers for Oxymorphone

The production and supply of oxymorphone API are concentrated across select geographic regions, primarily China, India, and certain Western countries, due to their established pharmaceutical manufacturing infrastructure.

1. Chinese API Manufacturers

China dominates the production of oxymorphone API, owing to its extensive pharmaceutical manufacturing capacity and cost advantages. Notable Chinese API producers are often GMP-certified, exporting globally to major pharmaceutical firms.

Major Chinese API Suppliers:

Zhejiang NHU Co., Ltd.
One of the leading Chinese pharmaceutical ingredients manufacturers, NHU offers oxymorphone APIs with high purity standards. Their facilities are frequently inspected by international regulatory bodies, including the FDA and EMA [1].
Hubei Hongyan Pharmaceutical Co., Ltd.
Recognized for manufacturing narcotic APIs, including oxymorphone, with a focus on regulatory compliance and quality assurance.
Sichuan Shengda Pharmaceutical Co., Ltd.
Offers bulk oxymorphone API, exporting to North America and Europe.

Strengths and Challenges:

Chinese API sources are valued for competitive pricing and high-volume production capacity. However, compliance with international regulations requires rigorous quality management, ongoing inspections, and certifications.

2. Indian API Producers

India’s pharmaceutical industry is renowned for its API manufacturing expertise, including complex opioids. Indian API manufacturers often possess WHO-GMP and other certifications, facilitating export to regulated markets.

Leading Indian API Suppliers:

Sun Pharmaceutical Industries Ltd.
Provides oxymorphone APIs through its API manufacturing subsidiaries, adhering to global standards.
Aarti Drugs Ltd.
Offers high-quality APIs with established export channels to North America and Europe.
Laurus Labs
Known for their broad portfolio of pharmaceutical APIs, including selective opioid compounds.

Advantages and Risks:

India's API industry is recognized for robust quality systems and cost efficiency. Regulatory vigilance remains critical, with ongoing inspections required to maintain GMP certifications for export.

3. Western and Emerging Market API Sources

Limited but strategic sources exist within Europe and North America, primarily for formulators requiring regional supply assurances. Western suppliers often have better-established regulatory credentials but at higher costs.

Pacira BioSciences:
Although primarily a pharmaceutical developer, occasionally sources APIs from certified suppliers for specialized formulations.
Domestic US/OEM APIs:
Certain manufacturers supply APIs for research, development, or regulatory-approved local manufacture but are less prominent in bulk commercial API supply for opioids like XTAMPZA ER.

Implication for Manufacturers:

The limited number of domestic or Western API producers necessitates reliance on Chinese and Indian suppliers for large-scale manufacturing, emphasizing the importance of thorough supplier qualification and compliance tracking.

Regulatory Considerations in API Sourcing

Given the controlled nature of oxymorphone APIs, sourcing is subject to extensive regulatory oversight. Key points include:

GMP Compliance:
Certification indicating adherence to the World Health Organization (WHO), FDA, or EMA standards ensures API suitability.
Inspection and Audits:
Regular on-site inspections and remote audits are required for suppliers, especially in jurisdictions with evolving regulatory regimes.
Traceability and Documentation:
Complete traceability from raw material sourcing through manufacturing is critical for regulatory audits.
Import/Export Controls:
As a controlled substance, APIs must comply with international narcotics regulations, including import/export licenses and secure transportation.

Market Trends and Future Outlook

The API supply chain for opioids like oxymorphone is evolving amid increasing global regulatory scrutiny, supply chain disruptions, and focus on drug abuse prevention.

Emerging Trends:

Diversification of Suppliers:
To reduce dependency, manufacturers seek multiple, compliant API sources.
Vertical Integration:
Some pharmaceutical companies invest in API manufacturing facilities to increase supply security.
Quality Certifications:
Growing emphasis on transparently verified GMP certifications aligned with international standards.
Legal and Regulatory Challenges:
Stricter import/export regulations, especially in the US and Europe, influence supplier selection and logistics.

Future Outlook:

While Chinese and Indian suppliers will continue to dominate the global API supply landscape, increased regulatory oversight and quality demands will likely lead to heightened scrutiny, mandating rigorous supplier qualification processes. Investment in manufacturing infrastructure and compliance will be essential for existing and emerging API producers aiming to serve the global market for XTAMPZA ER.

Key Takeaways

The primary bulk API sources for XTAMPZA ER are concentrated in China and India, offering cost-effective, high-quality oxymorphone hydrochloride, contingent on strict regulatory compliance.
Ensuring GMP-certified suppliers with current audit approvals and transparent documentation is critical for regulatory adherence.
Supply chain diversification mitigates risks associated with geopolitical tensions, regulatory shifts, and manufacturing disruptions.
Regulatory compliance, ongoing monitoring, and thorough supplier qualification are non-negotiable for manufacturers of controlled substances like XTAMPZA ER.
Future market stability depends on compliance investments, quality assurance processes, and adherence to evolving international narcotics regulations.

FAQs

1. What are the primary challenges in sourcing API for XTAMPZA ER?
Challenges include ensuring GMP compliance, preventing contamination, maintaining high purity standards, managing regulatory variations across countries, and mitigating supply chain disruptions.

2. How does regulatory oversight influence API supplier selection?
Regulators require comprehensive documentation, GMP certifications, and regular audits. Suppliers must demonstrate compliance with international standards, impacting choice and ongoing oversight.

3. Are there domestic sources for oxymorphone API in the US or Europe?
Limited domestic production exists; most APIs are sourced from China and India. Regulatory and capacity limitations constrict local supply, leading to reliance on international suppliers.

4. What measures can manufacturers take to ensure API quality?
Comprehensive supplier qualification, qualification audits, routine in-process controls, adherence to validated manufacturing processes, and rigorous batch testing are essential.

5. How might future regulatory changes impact API sourcing?
Tighter controls and restrictions on controlled substances could limit supplier options, increase compliance costs, and necessitate greater transparency in documentation and traceability.

References

[1] U.S. Food and Drug Administration. (2022). Inspection and Certification of Pharmaceutical Manufacturers.
[2] World Health Organization. (2021). Guidelines on Good Manufacturing Practices.
[3] European Medicines Agency. (2022). Regulatory Requirements for APIs.
[4] Chinese Pharmacopoeia. (2023). Standards for Pharmaceutical Raw Materials.
[5] Indian Pharmacopoeia Commission. (2022). API Quality Standards.

Bulk Pharmaceutical API Sources for XTAMPZA ER